Specialty
Aesthetics Cardiology Cataract & Refractive Dermatology General Ophthalmology Glaucoma Interventional Cardiology Interventional Radiology Neurology Optometry Pain Management Retina Women's Health View All Courses
Course Type
Supplement Multimedia Webinar In-Person Multi-Part Collection
Search
Log In

DEF Biologic & Small Molecule NP/PA CME Virtual Bootcamp 2021

By: Joseph Gorelick, MSN, FNP-C; April Armstrong, MD, MPH; David Cohen, MD, MPH; Kara Gooding, MMS, PA-C

In Person Credits: 4

Expiration Date: Thursday, September 30, 2021
Release Date: March 6, 2021

Learning Objectives

Critically appraise and discuss recent findings on the immunopathogenesis of psoriasis, atopic dermatitis, psoriatic arthritis, and hidradenitis supperativa.

Describe recent advances in biologic and small molecule drug development for the treatment of immune-mediated inflammatory disease, with an emphasis on psoriasis, psoriatic arthritis, and atopic dermatitis.

Develop strategies to predict, prevent, and treat potential adverse effects and complications encountered with biologic agents.

Analyze recent clinical trials on the safety and efficacy of biologic and small molecule drugs for the treatment of psoriasis, psoriatic arthritis, and atopic dermatitis.

Review data regarding the comorbidities associated with psoriasis, psoriatic arthritis, and atopic dermatitis.

Through case-based presentations and discussion, develop individualized treatment plans for patients with psoriasis or AD.

 

Accreditation and Designation Statement

Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Evolve Medical Education, LLC and the Dermatology Education Foundation. Evolve Medical Education, LLC is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement
Evolve Medical Education, LLC designates this live activity for a maximum of 4 AMA PRA Category 1 Credits TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

PA CONTINUING EDUCATION
PAs may claim a maximum of 4 Category 1 credits for completing this activity. National Commission on Certification of Physician Assistants (NCCPA) accepts AMA PRA Category 1 CreditsTM from organizations accredited by ACCME or a recognized state medical society.

NURSE PRACTITIONER CONTINUING EDUCATION
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts certificates of participation for educational activities certified for AMA PRA Category 1 CreditsTM  from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.

This activity is designated for 2.25 pharmacology credits.

Faculty and Disclosures

  • April Armstrong has had a financial agreement or affiliation during the past year with the following commercial interests in the form of: Consultant: AbbVie, BI, Bristol-Myers Squibb, Dermira, Dermavant, Eli Lilly, EPI Health, Incyte, Janssen, LEO Pharma, Modernizing Medicine, Novartis AG, Ortho Dermatologics, Pfizer, Regeneron Pharmaceuticals, Sun Pharma, and UCB. Non-Promotional Speaker: AbbVie, Janssen. Grant/Research Support: Bristol-Myers Squibb, Dermavant, Dermira, Eli Lilly, and UCB.
  • David Cohen, MD, MPH, FAAD has had a financial agreement or affiliation during the past year with the following commercial interests in the form of: Consultant: Asana, Cosmetic Ingredient Review, Dermavant, Ferndale Laboratories, FIDE, FSJ, LEO, Medimetriks, Novartis, and UCB. Stock Shareholder: Brickell Biotech (past), Dermira (past), Kadmon, Medimetriks (past) and Timber Pharmaceuticals. Board of Directors: Dermira (past), Evommune, Kadmon, and Timber.
  • Kara Gooding, MMS, PA-C has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Incyte, Novartis Pharmaceuticals, Pfizer, and UCB. Speaker’s Bureau: Amgen, Almirall, LEO Pharma, and Pfizer.
  • Joseph Gorelick, MSN, FNP-C has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Bristol Myers Squibb, Beiersdorf, Brickell, Incyte, Journey, and Novartis. Speaker’s Bureau: AbbVie, Beiersdorf, Janssen, Lilly, LEO, Novartis, Pfizer, Prugen, Regeneron Pharmaceuticals, Sanofi Genzyme, Sun Pharma,
    and Vyne. Stock Shareholder: 10X Genomics, AbbVie (past), Alnilam Pharmaceuticals, Bioline Rx, Fortress Biotech, G1 Therapeutics, Guardiant Health, Intuitive Surgical, LTD, Moderna, and Royalty Pharma.
  • Accreditation and Medical Education Support Disclosure
    Erin Fletcher of Evolve Medical Education LLC have no real or apparent conflicts of interest to report. Stacey Moore of Physician Resources, LLC has no real or apparent conflicts of interest to report.

 

 

 

Test

Instructions

Step 1 of 2

  • AgreeNeutralDisagree
    Critically appraise and discuss recent findings on the immunopathogenesis of psoriasis, atopic dermatitis, psoriatic arthritis, and hidradenitis supperativa.
    Describe recent advances in biologic and small molecule drug development for the treatment of immune-mediated inflammatory disease, with an emphasis on psoriasis, psoriatic arthritis, and atopic dermatitis
    Develop strategies to predict, prevent, and treat potential adverse effects and complications encountered with biologic agents
    Analyze recent clinical trials on the safety and efficacy of biologic and small molecule drugs for the treatment of psoriasis, psoriatic arthritis, and atopic dermatitis
    Review data regarding the comorbidities associated with psoriasis, psoriatic arthritis, and atopic dermatitis
    Through case-based presentations and discussion, develop individualized treatment plans for patients with psoriasis or AD.
Back